Insider Selling: CareDx, Inc (NASDAQ:CDNA) Insider Sells 20,000 Shares of Stock


Share on StockTwits

CareDx, Inc (NASDAQ:CDNA) insider Peter Maag sold 20,000 shares of the business’s stock in a transaction on Monday, May 3rd. The stock was sold at an average price of $76.64, for a total value of $1,532,800.00.

Peter Maag also recently made the following trade(s):

  • On Monday, April 5th, Peter Maag sold 10,000 shares of CareDx stock. The shares were sold at an average price of $72.40, for a total value of $724,000.00.
  • On Friday, March 5th, Peter Maag sold 10,000 shares of CareDx stock. The stock was sold at an average price of $61.29, for a total transaction of $612,900.00.
  • On Friday, February 5th, Peter Maag sold 10,000 shares of CareDx stock. The shares were sold at an average price of $89.82, for a total transaction of $898,200.00.

NASDAQ:CDNA traded down $3.24 during mid-day trading on Tuesday, hitting $74.08. The stock had a trading volume of 541,966 shares, compared to its average volume of 724,648. The company’s 50 day simple moving average is $72.04 and its 200 day simple moving average is $70.69. The stock has a market cap of $3.85 billion, a price-to-earnings ratio of -161.04 and a beta of 0.84. CareDx, Inc has a twelve month low of $26.61 and a twelve month high of $99.83.

CareDx (NASDAQ:CDNA) last released its quarterly earnings data on Tuesday, February 23rd. The company reported $0.08 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.12) by $0.20. The company had revenue of $58.64 million during the quarter, compared to analysts’ expectations of $58.51 million. CareDx had a negative return on equity of 10.95% and a negative net margin of 11.79%. Equities analysts anticipate that CareDx, Inc will post -0.47 earnings per share for the current year.

CDNA has been the subject of a number of research reports. HC Wainwright lowered shares of CareDx from a “buy” rating to a “neutral” rating in a report on Friday, February 26th. Piper Sandler boosted their price target on shares of CareDx from $62.00 to $93.00 and gave the company an “overweight” rating in a report on Tuesday, January 12th. Raymond James decreased their target price on CareDx from $101.00 to $98.00 and set a “strong-buy” rating for the company in a research note on Wednesday, March 3rd. Zacks Investment Research raised CareDx from a “sell” rating to a “hold” rating in a research report on Tuesday, April 27th. Finally, Craig Hallum boosted their price objective on CareDx from $66.00 to $94.00 and gave the company a “buy” rating in a research report on Monday, January 4th. Two investment analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company. The stock has an average rating of “Buy” and an average price target of $73.57.

A number of hedge funds have recently added to or reduced their stakes in the business. Cowa LLC acquired a new position in shares of CareDx in the fourth quarter valued at $32,000. Capital Asset Advisory Services LLC acquired a new position in CareDx in the 4th quarter valued at about $32,000. IFP Advisors Inc raised its holdings in CareDx by 16,600.0% in the 1st quarter. IFP Advisors Inc now owns 501 shares of the company’s stock valued at $34,000 after acquiring an additional 498 shares during the period. Advisory Services Network LLC lifted its position in CareDx by 22.0% during the fourth quarter. Advisory Services Network LLC now owns 638 shares of the company’s stock worth $46,000 after acquiring an additional 115 shares during the last quarter. Finally, Orion Capital Management LLC bought a new stake in shares of CareDx during the fourth quarter worth approximately $51,000.

About CareDx

CareDx, Inc discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It offers AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; and AlloSure Heart, a dd-cfDNA test to identify underlying cell injury leading to organ rejection.

Recommended Story: Fundamental Analysis

Insider Buying and Selling by Quarter for CareDx (NASDAQ:CDNA)

Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.